Valuation: Beta Bionics, Inc.

Market Cap 626M 543M 508M 465M 877M 59.52B 890M 5.95B 2.33B 29.81B 2.35B 2.3B 99.19B P/E 2026 *
-6.5x
P/E 2027 * -6.46x
Enterprise Value 488M 424M 397M 363M 685M 46.46B 695M 4.64B 1.82B 23.27B 1.83B 1.79B 77.42B EV / Sales 2026 *
3.65x
EV / Sales 2027 * 3.03x
Free-Float
98.92%
Yield 2026 *
-
Yield 2027 * -
1 day+1.44%
1 week-6.99%
Current month+9.98%
1 month-15.81%
3 months+40.96%
6 months+6.57%
Current year-53.69%
1 week 12.73
Extreme 12.73
14.68
1 month 12.73
Extreme 12.73
18.2
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 50 15/08/2022
Director/Board Member 63 01/10/2024
Date Insider Type Main position Quantity % Market Cap.
6/24/26 A Sell

Executive/Senior Manager

-1,258 0.0028%
2/27/26 A Free

Chief Technology Officer

110,131 0.2502%
2/27/26 A Sell

Executive/Senior Manager

59,813 0.1359%
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%-6.99%-10.75% - 626M
+0.38%+0.62%+24.36%+5.72% 214B
+0.16%+1.78%+0.47%-21.50% 140B
-0.40%+5.84%-21.65%+20.82% 133B
+3.27%+7.08%-52.97%-2.80% 69.19B
+0.39%+4.15%+12.72%+12.28% 51.28B
-0.36%+4.16%-14.57%-20.67% 50.43B
+0.16%+0.74%+23.02%+11.91% 39.85B
-0.08%+5.33%+42.15%+37.88% 39.27B
-0.35%+4.18%-21.67%+24.54% 32.32B
Average +0.46%+2.56%-1.89%+7.58% 76.95B
Weighted average by Cap. +0.35%+3.03%+0.67%+4.05%

Financials

2026 *2027 *
Net sales 134M 116M 109M 99.48M 188M 12.73B 190M 1.27B 499M 6.37B 502M 491M 21.21B 180M 156M 146M 134M 252M 17.1B 256M 1.71B 671M 8.56B 675M 660M 28.49B
Net income -95.09M -82.53M -77.26M -70.69M -133M -9.04B -135M -904M -355M -4.53B -357M -349M -15.07B -96.42M -83.68M -78.34M -71.68M -135M -9.17B -137M -917M -360M -4.59B -362M -354M -15.28B
Net Debt -137M -119M -112M -102M -192M -13.06B -195M -1.31B -512M -6.54B -516M -504M -21.77B -81.06M -70.36M -65.86M -60.26M -114M -7.71B -115M -771M -302M -3.86B -304M -298M -12.85B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
06/08/26 $14.11 +1.44% 590,143
05/08/26 $13.91 -4.53% 897,075
04/08/26 $14.57 +9.14% 3,341,441
03/08/26 $13.35 +4.05% 2,820,101
31/07/26 $12.83 -10.09% 2,004,597
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
13.91USD
Average target price
20.08USD
Spread / Average Target
+44.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock